NEW YORK (GenomeWeb News) - Molecular diagnostic test maker BioTheranostics said today that Lab21 will market and sell one of its cancer tests in the UK, Ireland, and in Middle East countries.

The BioMerieux subsidiary said that the two-year commercialization agreement covers its Theros CancerType ID cancer classifier test. The 92-gene test identifies 39 types of tumors and 64 sub-types, and is used to help doctors guide their treatment decisions for cancer patients whose tumor sites are uncertain or unknown.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.